Search This Blog

Wednesday, July 9, 2025

Neurizon Therapeutics Advances Towards Lifting FDA Hold on ALS Treatment

 

  • Neurizon received FDA feedback on lifting the clinical hold for NUZ-001.

  • The company aims to join the HEALEY ALS Trial in Q4 2025.

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)